Protara Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 27
- Market Cap
- $42.4M
- Website
- http://www.protaratx.com
- Introduction
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
FDA fast tracks Protara's choline chloride therapy
FDA grants Fast Track designation to Protara Therapeutics' IV Choline Chloride for patients requiring parenteral support, aiming to address choline deficiency. THRIVE-3 trial scheduled for Q1 2025 to assess safety and efficacy. No approved IV choline products exist globally.
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride
Protara Therapeutics receives FDA Fast Track designation for IV Choline Chloride, intended for PS-dependent patients unable to receive sufficient nutrition orally or enterally. Approximately 80% of PS-dependent patients experience choline deficiency, leading to severe health complications. Protara plans to initiate the registrational THRIVE-3 clinical trial in Q1 2025 to assess the safety and efficacy of IV Choline Chloride.
© Copyright 2025. All Rights Reserved by MedPath